LEXINGTON, Mass — BioScale, Inc. a life science company that develops ultrasensitive protein analysis technology, today announced the appointment of Martin Latterich, PhD as Chief Scientific Officer (CSO). Dr. Latterich brings nearly 20 years of academic, commercial and technology development experience to BioScale and features an accomplished research career focused on the proteomics-based discovery of novel biomarkers in oncology, respiratory disease and neurodegenerative disorders.

We are extremely pleased to welcome Martin to BioScale,” commented Mark Lundstrom, BioScale CEO. “His scientific leadership and experience in proteomics along with his ability to recognize and develop cutting-edge technology and implement scientific strategies into measurable results will be beneficial to the continued growth of our ViBE platform and AMMP technology commercialization.”

“I was very attracted to BioScale’s unique assay technology and platform capabilities that will finally enable a continuous pathway for pharma and biotech from the R&D lab to personalized patient care,” said Dr. Latterich. “I look forward to establishing relationships and innovative collaborations that will showcase this exceptional protein platform and contribute to BioScale’s growth and continued success.”

Most recently Martin served as a Professor at the Proteogenomics Research Institute for Systems Medicine in San Diego, where his laboratory used proteomics and genomics to discover novel biomarkers of cancer and degenerative disease though a systems biology approach that includes proteomics. He is also the CSO, co-founder and a board member for the non-profit Nicholas Conor Institute for Pediatric Cancer Research. Martin’s work at the institute included designing new technologies to enable the better treatment of children with cancer, using personalized medicine technology to match their unique genetic make-up and tumor physiology to available treatment options. He previously served on the faculty of the University of Montreal, McGill University and the Salk Institute. His grant-funded work has been recognized by the 2003 Tier I Canada Research Chair, the 1998 Pew Scholar Award and the 1997 Basil O’Connor Starter Scholar Award.

Dr. Latterich also held senior management positions at several biotechnology companies, including Diversa and Illumina, where he headed the proteomics initiatives. He has made significant contributions to the field of cell biology, clinical biomarker discovery, proteomics and genomics. Among his recent discoveries are biomarkers for cancer, respiratory disease and neurodegenerative disorders. Dr Latterich has edited one book on RNAi, is author on over 32 publications in leading scientific journals and is listed on numerous patent applications. Martin is Editor-in-Chief of the scientific journal Proteome Science. He has served on several national and international study sections. He was a postdoctoral fellow in molecular and cell biology in the laboratory of Dr. Randy Schekman at the HHMI and University of California, Berkeley. Dr. Latterich earned his Ph.D. in cell biology and a B.Sc. in biochemistry and molecular biology from Durham University, U.K.

About BioScale, Inc.

BioScale is a life science company that develops, manufactures and promotes a proprietary protein analysis technology to accelerate the discovery, development and production of biological and pharmaceutical products. BioScale’s innovative ViBE™ platform powered by its AMMP™ (Acoustic Membrane Microparticle) technology enables highly-sensitive detection and quantitation of proteins in complex samples used in pre-clinical and clinical research, bioprocess, patient point-of-care and personalized medicine applications. BioScale is headquartered in Lexington, MA. For more information, visit www.bioscale.com.